Aktieanalys

Alzecure: Abstract on Potential Disease-modifying Benefits of ACD856 Accepted - Redeye

Redeye Publicerad: 30 Aug 2022 13:59

Redeye endorses today’s news that Alzecure will present an abstract in October, which indicates (from pre-clinical research) that its lead candidate from Neurorestore, ACD856, potentially has disease-modifying properties (in addition to memory enhancement). We think that this could be very exciting, and it could increase the value of the treatment significantly if replicated in the clinic. We will return with an interview with Alzecure this week to further discuss the finding.

Länk till analysen i sin helhet: https://www.redeye.se/research/854171/alzecure-abstract-on-potential-disease-modifying-benefits-of-acd856-accepted?utm_source=finwire&utm_medium=RSS

Nyheter om AlzeCure Pharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!